Literature DB >> 19451301

Inhibitory effects of lactoferrin on growth and biofilm formation of Porphyromonas gingivalis and Prevotella intermedia.

Hiroyuki Wakabayashi1, Koji Yamauchi, Tetsuo Kobayashi, Tomoko Yaeshima, Keiji Iwatsuki, Hiromasa Yoshie.   

Abstract

Lactoferrin (LF) is an iron-binding antimicrobial protein present in saliva and gingival crevicular fluids, and it is possibly associated with host defense against oral pathogens, including periodontopathic bacteria. In the present study, we evaluated the in vitro effects of LF-related agents on the growth and biofilm formation of two periodontopathic bacteria, Porphyromonas gingivalis and Prevotella intermedia, which reside as biofilms in the subgingival plaque. The planktonic growth of P. gingivalis and P. intermedia was suppressed for up to 5 h by incubation with >or=130 microg/ml of human LF (hLF), iron-free and iron-saturated bovine LF (apo-bLF and holo-bLF, respectively), and >or=6 microg/ml of bLF-derived antimicrobial peptide lactoferricin B (LFcin B); but those effects were weak after 8 h. The biofilm formation of P. gingivalis and P. intermedia over 24 h was effectively inhibited by lower concentrations (>or=8 microg/ml) of various iron-bound forms (the apo, native, and holo forms) of bLF and hLF but not LFcin B. A preformed biofilm of P. gingivalis and P. intermedia was also reduced by incubation with various iron-bound bLFs, hLF, and LFcin B for 5 h. In an examination of the effectiveness of native bLF when it was used in combination with four antibiotics, it was found that treatment with ciprofloxacin, clarithromycin, and minocycline in combination with native bLF for 24 h reduced the amount of a preformed biofilm of P. gingivalis compared with the level of reduction achieved with each agent alone. These results demonstrate the antibiofilm activity of LF with lower iron dependency against P. gingivalis and P. intermedia and the potential usefulness of LF for the prevention and treatment of periodontal diseases and as adjunct therapy for periodontal diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19451301      PMCID: PMC2715627          DOI: 10.1128/AAC.01688-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

Review 1.  The antimicrobial treatment of periodontal disease: changing the treatment paradigm.

Authors:  W J Loesche
Journal:  Crit Rev Oral Biol Med       Date:  1999

Review 2.  Antimicrobial actions of lactoferrin.

Authors:  R Chierici
Journal:  Adv Nutr Res       Date:  2001

3.  A component of innate immunity prevents bacterial biofilm development.

Authors:  Pradeep K Singh; Matthew R Parsek; E Peter Greenberg; Michael J Welsh
Journal:  Nature       Date:  2002-05-30       Impact factor: 49.962

Review 4.  Bovine lactoferrin and lactoferricin derived from milk: production and applications.

Authors:  M Tomita; H Wakabayashi; K Yamauchi; S Teraguchi; H Hayasawa
Journal:  Biochem Cell Biol       Date:  2002       Impact factor: 3.626

Review 5.  Clinical applications of antimicrobial host proteins lactoperoxidase, lysozyme and lactoferrin in xerostomia: efficacy and safety.

Authors:  J Tenovuo
Journal:  Oral Dis       Date:  2002-01       Impact factor: 3.511

6.  Efficacy of antibiotics to strains of periodontopathogenic bacteria within a single species biofilm - an in vitro study.

Authors:  S Eick; T Seltmann; W Pfister
Journal:  J Clin Periodontol       Date:  2004-05       Impact factor: 8.728

7.  Oral lactoferrin treatment of experimental oral candidiasis in mice.

Authors:  Natsuko Takakura; Hiroyuki Wakabayashi; Hiroko Ishibashi; Susumu Teraguchi; Yoshitaka Tamura; Hideyo Yamaguchi; Shigeru Abe
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

Review 8.  Lactoferricin derived from milk protein lactoferrin.

Authors:  H Wakabayashi; M Takase; M Tomita
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

9.  Susceptibility of Porphyromonas gingivalis in biofilms to amoxicillin, doxycycline and metronidazole.

Authors:  T Larsen
Journal:  Oral Microbiol Immunol       Date:  2002-10

10.  Evaluation of the antimicrobial effect of lactoferrin on Porphyromonas gingivalis, Prevotella intermedia and Prevotella nigrescens.

Authors:  O Aguilera; M T Andrés; J Heath; J F Fierro; C W Douglas
Journal:  FEMS Immunol Med Microbiol       Date:  1998-05
View more
  30 in total

1.  Effects of a composition containing lactoferrin and lactoperoxidase on oral malodor and salivary bacteria: a randomized, double-blind, crossover, placebo-controlled clinical trial.

Authors:  Kouichirou Shin; Ken Yaegaki; Takatoshi Murata; Hisataka Ii; Tomoko Tanaka; Izumi Aoyama; Koji Yamauchi; Tomohiro Toida; Keiji Iwatsuki
Journal:  Clin Oral Investig       Date:  2010-05-29       Impact factor: 3.573

Review 2.  Immunomodulatory effects of lactoferrin.

Authors:  Tania Siqueiros-Cendón; Sigifredo Arévalo-Gallegos; Blanca Flor Iglesias-Figueroa; Isui Abril García-Montoya; José Salazar-Martínez; Quintín Rascón-Cruz
Journal:  Acta Pharmacol Sin       Date:  2014-05       Impact factor: 6.150

3.  Lactoferrin inhibits Porphyromonas gingivalis proteinases and has sustained biofilm inhibitory activity.

Authors:  Stuart G Dashper; Yu Pan; Paul D Veith; Yu-Yen Chen; Elena C Y Toh; Sze Wei Liu; Keith J Cross; Eric C Reynolds
Journal:  Antimicrob Agents Chemother       Date:  2012-01-03       Impact factor: 5.191

Review 4.  Interdependence between iron acquisition and biofilm formation in Pseudomonas aeruginosa.

Authors:  Donghoon Kang; Natalia V Kirienko
Journal:  J Microbiol       Date:  2018-06-14       Impact factor: 3.422

5.  Effects of bovine lactoferrin to oral Candida albicans and Candida glabrata isolates recovered from the saliva in elderly people.

Authors:  Akino Komatsu; Tazuko Satoh; Hiroyuki Wakabayashi; Fumiaki Ikeda
Journal:  Odontology       Date:  2015-01       Impact factor: 2.634

6.  Anaerobic Bacterial Fermentation Products Increase Tuberculosis Risk in Antiretroviral-Drug-Treated HIV Patients.

Authors:  Leopoldo N Segal; Jose C Clemente; Yonghua Li; Chunhai Ruan; Jane Cao; Mauricio Danckers; Alison Morris; Sarah Tapyrik; Benjamin G Wu; Philip Diaz; Gregory Calligaro; Rodney Dawson; Richard N van Zyl-Smit; Keertan Dheda; William N Rom; Michael D Weiden
Journal:  Cell Host Microbe       Date:  2017-03-30       Impact factor: 21.023

7.  Combined treatment of Pseudomonas aeruginosa biofilm with lactoferrin and xylitol inhibits the ability of bacteria to respond to damage resulting from lactoferrin iron chelation.

Authors:  Mary Cloud B Ammons; Loren S Ward; Scot Dowd; Garth A James
Journal:  Int J Antimicrob Agents       Date:  2011-03-05       Impact factor: 5.283

8.  Lactoferrin and oral diseases: current status and perspective in periodontitis.

Authors:  Francesca Berlutti; Andrea Pilloni; Miriam Pietropaoli; Antonella Polimeni; Piera Valenti
Journal:  Ann Stomatol (Roma)       Date:  2012-01-27

9.  A high-throughput method for the quantification of iron saturation in lactoferrin preparations.

Authors:  Grzegorz Majka; Klaudyna Śpiewak; Katarzyna Kurpiewska; Piotr Heczko; Grażyna Stochel; Magdalena Strus; Małgorzata Brindell
Journal:  Anal Bioanal Chem       Date:  2013-04-21       Impact factor: 4.142

10.  Evaluating protein binding specificity of titanium surfaces through mass spectrometry-based proteomics.

Authors:  David Zuanazzi; Yizhi Xiao; Walter L Siqueira
Journal:  Clin Oral Investig       Date:  2020-09-01       Impact factor: 3.573

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.